Document Detail


Respiratory syncytial virus disease: update on treatment and prevention.
MedLine Citation:
PMID:  21171875     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in infants and young children, accounting for more than 100,000 hospitalizations per year in the USA. The majority of hospitalizations occur in infants less than 1 year of age. Worldwide, RSV is associated with an annual mortality rate of 160,000-600,000 deaths. Premature infants, and infants with congenital heart disease, neuromuscular disease, structural airway abnormalities and immunodeficiencies are at increased risk for severe RSV disease. Despite the magnitude of RSV disease, treatment remains primarily supportive. Trials of bronchodilators, corticosteroids and montelukast have not demonstrated conclusive clinical benefit. The antiviral drug ribavirin has demonstrated only marginal clinical benefit and is not routinely indicated in treatment of RSV disease. Palivizumab is beneficial in prophylaxis for infants at high-risk for severe RSV infection although optimal indications based on cost-effectiveness considerations have not been defined. Future directions in treatment and prevention of RSV infections likely include the second-generation monoclonal antibody motavizumab, more potent antiviral compounds and more unique anti-inflammatory agents. Vaccination against RSV is in development but not eminent.
Authors:
Leonard R Krilov
Related Documents :
11266055 - Social patterns of birth weight in hong kong, 1984-1997.
18242685 - Investigating the behavioural and physiological indicators of neonatal survival in pigs.
18450655 - Birth weight of infants after maternal exposure to typical and atypical antipsychotics:...
21261445 - Periodontal disease and bacterial vaginosis as genetic and environmental markers for th...
9309915 - Improved perinatal outcomes with perinatal case management.
16238565 - Early complication of pediatric central venous cannulation.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of anti-infective therapy     Volume:  9     ISSN:  1744-8336     ISO Abbreviation:  Expert Rev Anti Infect Ther     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-21     Completed Date:  2011-03-28     Revised Date:  2011-07-29    
Medline Journal Info:
Nlm Unique ID:  101181284     Medline TA:  Expert Rev Anti Infect Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  27-32     Citation Subset:  IM    
Affiliation:
Winthrop University Hospital, Mineola, NY, USA. lkrilov@winthrop.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Antiviral Agents / therapeutic use*
Bronchiolitis, Viral / drug therapy,  prevention & control,  virology
Bronchodilator Agents / therapeutic use
Child
Clinical Trials as Topic
Humans
Infant
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / drug therapy*,  prevention & control*,  virology
Respiratory Syncytial Virus Infections / drug therapy*,  prevention & control*,  virology
Respiratory Syncytial Virus, Human
Respiratory Tract Infections / drug therapy,  prevention & control,  virology
Ribavirin / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antibodies, Monoclonal; 0/Antiviral Agents; 0/Bronchodilator Agents; 0/motavizumab; 0/palivizumab; 36791-04-5/Ribavirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Control of hepatitis B in China: prevention and treatment.
Next Document:  Hantavirus protein interactions regulate cellular functions and signaling responses.